XML 68 R61.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details) - shares
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities 28,001,227 27,476,681 26,988,026 24,548,119
Common Stock Options Granted        
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities 13,055,050 14,556,602 13,070,461 14,180,632
Nonvested Restricted Stock Units Outstanding        
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities 11,174,598 11,007,405 10,757,897 8,956,361
Nonvested Market-based Restricted Stock Units Outstanding Granted        
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities 3,771,579 1,912,674 3,159,668 1,411,126